The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing

Recent clinical trials of mesenchymal stromal cell (MSC) therapy for various inflammatory conditions have highlighted the significant benefit to patients who respond to MSC administration. Thus, there is strong interest in investigating MSC therapy in acute inflammatory lung conditions, such as acut...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hazel Dunbar, Daniel J Weiss, Sara Rolandsson Enes, John G Laffey, Karen English
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	MSC licensing lung microenvironment inflammatory cytokines Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/207e4121b9d74c4aa142f895cdf33e4e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:207e4121b9d74c4aa142f895cdf33e4e
record_format	dspace
spelling	oai:doaj.org-article:207e4121b9d74c4aa142f895cdf33e4e2021-11-25T17:09:59ZThe Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing10.3390/cells101129822073-4409https://doaj.org/article/207e4121b9d74c4aa142f895cdf33e4e2021-11-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/2982https://doaj.org/toc/2073-4409Recent clinical trials of mesenchymal stromal cell (MSC) therapy for various inflammatory conditions have highlighted the significant benefit to patients who respond to MSC administration. Thus, there is strong interest in investigating MSC therapy in acute inflammatory lung conditions, such as acute respiratory distress syndrome (ARDS). Unfortunately, not all patients respond, and evidence now suggests that the differential disease microenvironment present across patients and sub-phenotypes of disease or across disease severities influences MSC licensing, function and therapeutic efficacy. Here, we discuss the importance of licensing MSCs and the need to better understand how the disease microenvironment influences MSC activation and therapeutic actions, in addition to the need for a patient-stratification approach.Hazel DunbarDaniel J WeissSara Rolandsson EnesJohn G LaffeyKaren EnglishMDPI AGarticleMSClicensinglungmicroenvironmentinflammatorycytokinesBiology (General)QH301-705.5ENCells, Vol 10, Iss 2982, p 2982 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	MSC licensing lung microenvironment inflammatory cytokines Biology (General) QH301-705.5
spellingShingle	MSC licensing lung microenvironment inflammatory cytokines Biology (General) QH301-705.5 Hazel Dunbar Daniel J Weiss Sara Rolandsson Enes John G Laffey Karen English The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing
description	Recent clinical trials of mesenchymal stromal cell (MSC) therapy for various inflammatory conditions have highlighted the significant benefit to patients who respond to MSC administration. Thus, there is strong interest in investigating MSC therapy in acute inflammatory lung conditions, such as acute respiratory distress syndrome (ARDS). Unfortunately, not all patients respond, and evidence now suggests that the differential disease microenvironment present across patients and sub-phenotypes of disease or across disease severities influences MSC licensing, function and therapeutic efficacy. Here, we discuss the importance of licensing MSCs and the need to better understand how the disease microenvironment influences MSC activation and therapeutic actions, in addition to the need for a patient-stratification approach.
format	article
author	Hazel Dunbar Daniel J Weiss Sara Rolandsson Enes John G Laffey Karen English
author_facet	Hazel Dunbar Daniel J Weiss Sara Rolandsson Enes John G Laffey Karen English
author_sort	Hazel Dunbar
title	The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing
title_short	The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing
title_full	The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing
title_fullStr	The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing
title_full_unstemmed	The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing
title_sort	inflammatory lung microenvironment; a key mediator in msc licensing
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/207e4121b9d74c4aa142f895cdf33e4e
work_keys_str_mv	AT hazeldunbar theinflammatorylungmicroenvironmentakeymediatorinmsclicensing AT danieljweiss theinflammatorylungmicroenvironmentakeymediatorinmsclicensing AT sararolandssonenes theinflammatorylungmicroenvironmentakeymediatorinmsclicensing AT johnglaffey theinflammatorylungmicroenvironmentakeymediatorinmsclicensing AT karenenglish theinflammatorylungmicroenvironmentakeymediatorinmsclicensing AT hazeldunbar inflammatorylungmicroenvironmentakeymediatorinmsclicensing AT danieljweiss inflammatorylungmicroenvironmentakeymediatorinmsclicensing AT sararolandssonenes inflammatorylungmicroenvironmentakeymediatorinmsclicensing AT johnglaffey inflammatorylungmicroenvironmentakeymediatorinmsclicensing AT karenenglish inflammatorylungmicroenvironmentakeymediatorinmsclicensing
_version_	1718412635794309120

The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing

Ejemplares similares